3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
103
Neoplasms, Plasma Cell
11
Immunoglobulin Light-chain Amyloidosis
11
Recurrence
10
Leukemia, Myeloid, Acute
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasm, Residual
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Paraproteinemias
3
Neoplasms
3
Lymphoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Waldenstrom Macroglobulinemia
2
Smoldering Multiple Myeloma
2
Prostatic Neoplasms
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Leukemia, Plasma Cell
2
Hodgkin Disease
2
Hematologic Diseases
2
Corneal Diseases
2
Blood Protein Disorders
2
Amyloidosis
2
Acute Kidney Injury
2
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Renal Insufficiency
1
Proteostasis Deficiencies
1
Primary Myelofibrosis
1
Plasmacytoma
1
Interventions
ofatumumab
1
daratumumab
1
Transcranial Direct Current Stimulation
1
Salpingo-oophorectomy
1
Rituximab
1
Magnetic Resonance Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
×
daratumumab
×
Clear all
NCT06867991
2025-07-15
RADIA
The First People's Hospital of Changzhou
Phase 3
Recruiting
200 enrolled